<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520230</url>
  </required_header>
  <id_info>
    <org_study_id>CP00011</org_study_id>
    <nct_id>NCT04520230</nct_id>
  </id_info>
  <brief_title>Three Treatment of Chronic Obstructive Pulmonary Disease Patients</brief_title>
  <official_title>Comparative Study Between Three Therapeutic Options for Treatment of Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty five COPD patients will be recruited from Chest Disease Department, Tanta University&#xD;
      Hospital, Tanta, Egypt.&#xD;
&#xD;
      The aim of the study is to Compare between the effectiveness of three therapeutic options for&#xD;
      treatment of moderate and severe COPD patients .These therapeutic options include Inhaled&#xD;
      corticosteroid (ICS) plus long acting B2-agonist (LABA) combination, Inhaled corticosteroid&#xD;
      (ICS) plus long acting anticholinergic (LAAC) combination and Long acting B2-agonist (LABA)&#xD;
      plus long acting anticholinergic (LAAC) combination .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be prospective randomized double blind study.&#xD;
&#xD;
      The forty five COPD patients will be divided into three groups:&#xD;
&#xD;
      Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting&#xD;
      B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).&#xD;
&#xD;
      Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting&#xD;
      anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).&#xD;
&#xD;
      Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long&#xD;
      acting anticholinergic (LAAC).&#xD;
&#xD;
      If any worsening of dyspnea, increase of purulence, or increase of sputum production appear&#xD;
      plus increase of peak variability more than 35% and FEV1 that necessitate a change of the&#xD;
      regular drug medication of the patient will be recorded as exacerbation.&#xD;
&#xD;
      All patients will be submitted to the following analysis at the baseline, during and 12 weeks&#xD;
      after the assigned treatment:&#xD;
&#xD;
        1. Full medical history will be taken through clinical assessment of dyspnea, chronic cough&#xD;
           and sputum production using mMRC or CAT test.&#xD;
&#xD;
        2. Forced expiratory volume in 1second (FEV1) value measurement using spirometry.&#xD;
&#xD;
        3. Measurement of the following inflammatory markers in serum and/ or plasma of patients&#xD;
           under study .&#xD;
&#xD;
             -  Tumer necrosis factor alpha ( TNF )&#xD;
&#xD;
             -  Fibrinogen&#xD;
&#xD;
             -  Interlukin 6 ( IL6 )&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      The results will be statistically calculated to evaluate its clinical significance if any&#xD;
      before ,during and after drug therapy using (ANOVA) system SPSS version 20 (2012) to compare&#xD;
      between the three groups of patients and paired t-test will be used to compare between&#xD;
      results before, during and after drug therapy .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2014</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized double blind prospective study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 value</measure>
    <time_frame>three months</time_frame>
    <description>Forced expiratory volume in 1second (FEV1) value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumer necrosis factor alpha ( TNF )</measure>
    <time_frame>three months</time_frame>
    <description>serum level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interlukin 6 ( IL6 )</measure>
    <time_frame>three months</time_frame>
    <description>serum level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Three months</time_frame>
    <description>serum level</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination (160/4.5mcg) 2 inhalations bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg inhaled capsule once daily+ Budesonide inhalation 200 mcg twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC). (Tiotropium 18 mcg inhaled capsule once daily+ Formoterol 12 mcg inhaled capsule twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid</intervention_name>
    <description>inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Budesonide/Formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 18 mcg capsule inhaled once daily + Budesonide</intervention_name>
    <description>inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Tiotropium/ Budesonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol/Tiotropium</intervention_name>
    <description>long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>LABA /LAAC.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 30 to 40 years or older.&#xD;
&#xD;
          2. Patient with 30%≥ FEV1&lt;80% predicted and FEV1/FVC &lt;70% predicted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with FEV1&lt; 30% predicted or FEV1&lt; 50% predicted plus chronic respiratory&#xD;
             failure.&#xD;
&#xD;
          2. Patients with recent chest infection or had been hospitalised for an exacerbation or&#xD;
             respiratory infection in the 6 weeks before screening.&#xD;
&#xD;
          3. Patients with history of asthma.&#xD;
&#xD;
          4. Patient with clinically significant condition ex; unstable ischemic heart disease,&#xD;
             uncontrolled hypertension, uncontrolled diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek M Mostafa, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <reference>
    <citation>Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.</citation>
    <PMID>21810710</PMID>
  </reference>
  <reference>
    <citation>Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008 May 1;5(4):506-12. doi: 10.1513/pats.200707-096ET. Review.</citation>
    <PMID>18453363</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Dr. Tarek Mohamed Mostafa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

